The text provides financial information from Johnson & Johnson, including consolidated balance sheets, statements of earnings, and comprehensive income for the fiscal third quarter and nine months ended October 1, 2023, with details on assets, liabilities, shareholders' equity, current assets, long-term debt, net earnings, earnings per share, and comprehensive income. It also discusses diluted net earnings per share calculation, focusing on stock options impact, and provides sales data for different business segments post-separation of the Consumer Health business, highlighting sales figures for various products within the Innovative Medicine and MedTech segments broken down by region and compared across different fiscal periods.
The text provided addresses various aspects of a company's financial and operational activities, including details on sales, analysis of financial performance by business segments (Innovative Medicine and MedTech), costs and expenses, restructuring programs, provision for taxes, cash flows, liquidity, capital resources, dividends, and new accounting pronouncements. Additionally, it discusses the impact of various geopolitical and economic factors like the Russia-Ukraine war and conflict in Israel, challenges in inflationary economies like Venezuela, Argentina, and Turkey, changes in tax laws, and healthcare industry challenges related to pricing pressure, intellectual property disputes, and changing consumer behavior due to economic conditions.
There have been no significant changes in the company's assessment of its market risk sensitivity since the details provided in the Annual Report on Form 10-K for the fiscal year ended January 1, 2023 were presented.
The text discusses the evaluation of disclosure controls and procedures by a company at the end of a reporting period. The controls and procedures are designed to ensure accurate and timely disclosure of information required by the Securities Exchange Act. The evaluation involved key executives, Joaquin Duato and Joseph J. Wolk, who concluded that the company's controls and procedures were effective. Additionally, there were no significant changes in the company's internal control over financial reporting during the period. The company continues to monitor and assess the effectiveness of its disclosure controls and procedures.
The text provided refers to legal proceedings being incorporated by reference to Note 11 in the financial statements as part of the disclosure process.
I am ready to receive and summarize the text parts you will provide.
The Company's Board of Directors approved a share repurchase program on September 14, 2022, allowing the purchase of up to $5 billion of Common Stock, which was completed in the first quarter of 2023. During the fiscal third quarter of 2023, the Company repurchased a total of 5,690,272 shares of Common Stock at an average price of $161.68 per share through open-market transactions as part of a systematic plan to meet the compensation program needs. The repurchase involved stock-for-stock option exercises. The table shows details of the Common Stock purchases in the respective fiscal months.
I am ready to assist you once you share the text parts you mentioned. Just send them over, and I will get started on summarizing the text for you.
I am ready to provide you with a summary once I receive the text parts.
On August 31, 2023, Peter Fasolo, the Executive Vice President and Chief Human Resources Officer, implemented a Rule 10b5-1 trading plan allowing for the sale of up to 25,000 shares of the company's Common Stock by November 29, 2024.
The text includes information about various exhibits filed with a document related to Johnson & Johnson, such as amendments to savings and incentive plans, certifications by CEO and CFO, and details on XBRL tags. The document's signing by authorized individuals from the company is also mentioned. This information pertains to the Securities Exchange Act of 1934 requirements and is dated October 27, 2023.
